Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection (TEPSTAR)

Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection. An Open-comparative Randomized Trial

S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci of Infection (SA-DFI), which require prolonged duration of antimicrobial therapy and specific treatment. Timely diagnosis and management of SA-DFI is associated with an improvement of prognosis during SAB. 18 FDG PET/CT (PET/CT) is a useful tool in the diagnosis of infectious foci during bacterial infections.

An ecological study performed in the Netherlands has shown that use of PET/CT in patients with Gram positive cocci bloodstream infection was associated with an increase of detection of DFI and a decrease of recurrences and mortality compared to historical controls.

The investigators hypothesize that SAB poor prognosis is in part related to the lack of diagnosis of all infectious foci and consequently to a suboptimal treatment.

Study Overview

• Status: Completed
• Conditions: Staphylococcus Aureus
• Intervention / Treatment: Procedure: PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions; Other: Patients' routine care with performance of explorations based on anamnesis and clinical symptoms

Detailed Description

Subjects will be recruited in medical wards of the 10 participating hospitals. Each included patient will be managed according to clinical expertise of investigators who all are experts in the field of infectious diseases. Consensual guidelines for antimicrobial therapy of patients enrolled in the study will be written before the enrolment of the first patient by the steering committee composed of all co-investigators These guidelines will specify the nature of empiric therapy as well as adapted antibiotic therapy for each specific DFI for methicillin-sensitive as well as for methicillin resistant S. aureus.

Experimental group: arm A All patients enrolled in arm A will have a PET/CT after enrolment and not later than day 14 after the drawing of first positive blood culture.

Control group: arm B Patients enrolled in arm B will not have PET/CT before day 14. Other imaging studies will be guided by anamnesis and clinical symptoms and performed according to guidelines written consensually before the enrolment of the first patient by the steering committee

• Study Type: Interventional
• Enrollment (Actual): 291
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • CHU Gui de Chauliac

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• - Aged over 18 years
• Signed informed consent form
• Subjects must be able to attend all scheduled visits and to comply with all trial procedures
• Subjects must be covered by public health insurance
• Hospitalized in one of the 10 participating centres
• At least one peripheral blood culture isolating S. aureus
• Absence of diagnosis of IE according to at least a transthoracic cardiac echography; cardiac echography will be performed via transesophageal procedure if the VIRSTA score is 3 or higher (see Appendix) or if transthoracic echography is not normal.

Exclusion Criteria:

• - Any reason that may compromise compliance with the visit plan
• Planned longer stay outside the region that prevents compliance with the visit plan
• Deprived of liberty subjects (by judicial or administrative decision)
• Adult under guardianshipCatheter-related SAB with resolution of symptoms of infection within 24 hours of ablation of catheter
• Pregnancy or lactation
• Isolation of S. aureus only in blood cultures drawn from a catheter or another implanted device
• Catheter-related SAB with resolution of symptoms of infection within 24 hours of ablation of catheter
• Uncontrolled septic shock and other instability contra-indicating the performance of PET/CT
• Previous performance of PET/CT for the present episode of SAB
• Indication to PET/CT for another reason (eg. neoplasm, infection of vascular graft…)
• Contra-indication to PET/CT
• Contraindication to Fluorodeoxyglucose : hypersensitivity to the active substance or to any of the excipients
• Participation to another study unless specific authorization of the steering committee

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: A: Patients with PET/CT performs at day 14 after the drawing; Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture	Procedure: PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions; Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required. Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community).
Placebo Comparator: B : Patients' routine care with performance of explorations; Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms	Other: Patients' routine care with performance of explorations based on anamnesis and clinical symptoms; Patients' routine care with performance of explorations based on anamnesis and clinical symptoms

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Presence of at least one DFI following the drawing of the first blood positive culture.	SA-DFI will be defined as the presence of at least one of the following criteria adapted form the criteria proposed by EMA for evaluation of antibiotics (EMA): Deep collection without any other explanation than S. aureus infection; Osteomyelitis or arthritis without any other explanation than S. aureus infection; in case of presence of material (osteosynthesis or prosthetic joint) the presence of clinical symptoms or bacteriological confirmation will be required because the specificity of imaging including PET/CT is low; Isolation of S. aureus in a sterile site other than blood, urine or catheter (eg: pleura, cerebrospinal fluid, bone, synovial fluid, muscle…)	day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PET/CT Evaluation :Frequency of SA-DFI	Frequency of SA-DFI according to the investigator	day 14
PET/CT Evaluation :Time to detection	Time to detection of DFI	day 14
Duration of Antibiotic treatment	Duration of antibiotic treatment	3 months
Duration of Antibiotic treatment	Duration of antibiotic treatment	6 months
frequency of Diagnostic procedures	frequency of procedures performed to treat SA-DFIs	3 months
frequency of Diagnostic procedures	frequency of procedures performed to treat SA-DFIs	6 months
Recurrences of S. aureus infection	Frequency of recurrences	3 months
Recurrences of S. aureus infection	Frequency of recurrences	6 months
Survival	Survival	3 months
Survival	Survival	6 months
Evaluation of the cost-effectiveness of strategies	Cost-effectiveness of strategies	3 months
Evaluation of the cost-effectiveness of strategies	Cost-effectiveness of strategies	6 months
Diagnostic procedures :Detection of endocardial hyperfixation	Detection of endocardial hyperfixation at PET/CT in arm A	3 months
Diagnostic procedures :Detection of endocardial hyperfixation	Detection of endocardial hyperfixation at PET/CT in arm A	6 months

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: Vincent LE MOING, Professor, Infectious Diseases department of CHU-Montpellier

Study record dates

Study Major Dates

• Study Start (Actual): January 29, 2018
• Primary Completion (Actual): March 20, 2025
• Study Completion (Actual): March 20, 2025

Study Registration Dates

• First Submitted: November 8, 2017
• First Submitted That Met QC Criteria: January 31, 2018
• First Posted (Actual): February 1, 2018

Study Record Updates

• Last Update Posted (Actual): April 18, 2025
• Last Update Submitted That Met QC Criteria: April 15, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Staphylococcus aureus; antibiotics; bloodstream infection; deep foci of infection; 18 FDG PET/CT
• Additional Relevant MeSH Terms: Pathologic Processes; Systemic Inflammatory Response Syndrome; Inflammation; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Staphylococcal Infections; Sepsis; Infections
• Other Study ID Numbers: UF 9788

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No